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Abstract
Background: The role of oral antibiotic therapy in treating infective endocarditis (IE) is not well established.
Methods: We searched MEDLINE, EMBASE and Scopus for studies in which oral antibiotic therapy was used for the
treatment of IE.
Results: Seven observational studies evaluating the use oral beta-lactams (five), oral ciprofloxacin in combination
with rifampin (one), and linezolid (one) for the treatment of IE caused by susceptible bacteria reported cure rates
between 77% and 100%. Two other observational studies using aureomycin or sulfonamide, however, had failure
rates >75%. One clinical trial comparing oral amoxicillin versus intravenous ceftriaxone for streptococcal IE reported
100% cure in both arms but its reporting had serious methodological limitations. One small clinical trial (n = 85)
comparing oral ciprofloxacin and rifampin versus conventional intravenous antibiotic therapy for uncomplicated
right-sided S. aureus IE in intravenous drug users (IVDUs) reported cure rates of 89% and 90% in each arm,
respectively (P =0.9); however, drug toxicities were more common in the latter group (62% versus 3%; P <0.01).
Major limitations of this trial were lack of allocation concealment and blinding at the delivery of the study drug(s)
and assessment of outcomes.
Conclusion: Reported cure rates for IE treated with oral antibiotic regimens vary widely. The use of oral
ciprofloxacin in combination with rifampin for uncomplicated right-sided S. aureus IE in IVDUs is supported by one
small clinical trial of relatively good quality and could be considered when conventional IV antibiotic therapy is not
possible.
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Background
The hallmark lesion of IE is the endocardial vegetation,
a meshwork of platelets, fibrin, bacteria and inflamma-
tory cells in which bacteria proliferate, invade adjacent
tissues, and disseminate as septic emboli [1,2]. So long
as bacteria are embedded in vegetations, the ability of
the immune system to assist with the eradication of
these organisms is greatly impaired [1,2]. This character-
istic underlies the concept, supported by experimental
and clinical observations, that high serum levels of bac-
tericidal antibiotics for prolonged periods of time are
needed for curing this infection [1-3]. Before the advent
of antibiotic therapy, infective endocarditis (IE) was in-
variably fatal.
Antibiotics delivered intravenously achieve rapid thera-
peutic concentrations in blood and perfused tissues, and
they are generally regarded as more potent and reliable
than their oral counterparts. For these reasons, intraven-
ous (IV) antibiotics are considered the cornerstone of IE
treatment [4]. The recommended duration of IV antibiotic
therapy for IE varies depending on the characteristics of
the infecting organism and the affected endocardial struc-
ture but in no instance it is <2 weeks and in most cases it
extends beyond 4 weeks [5]. However, there are instances
in which the options of effective intravenous antibiotics
are limited (patients with multiple allergies, resistant bac-
teria, etc.) or the maintenance of prolonged intravenous
access is not desirable (i.e. active intravenous drug users)
or at all feasible (i.e. patient’s inability to maintain intra-
vascular access). In these situations, oral antibiotic therapy
can be an attractive and convenient alternative. However,
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little is known about the value of this strategy in the set-
ting of IE.
Using a systematic approach, this review examines the
literature on the efficacy of oral antibiotic therapy in the
treatment of IE.
Methods
Our review protocol conformed to the Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [6].
Search strategy
Our systematic search strategy was developed to capture
all articles of IE in which oral antibiotic therapy was
used. We included articles reporting in English, French,
Spanish and Arabic languages. We searched the follow-
ing databases: MEDLINE (from 1948 to June 1, 2013),
EMBASE (from 1947 to June 1, 2013), and Scopus (from
1960 to June 1, 2013). Reference lists of selected papers
were also screened for additional articles of interest. The
search strategies used are presented in Additional file 1.
Eligibility criteria
We only included studies of IE in which the duration of
antibiotic treatment was >2 weeks and oral antibiotics
where the only antibiotics given after 2 weeks of treat-
ment initiation. To be eligible, studies had to a) report
mortality and clinical cure as their outcomes of interest;
b) report the microbiology of their IE cases; and c)
present their data in a way that it allowed for the calcu-
lation of outcome rates as a function of the entire study
cohort. Studies with focus on culture negative endocar-
ditis were excluded. We also excluded case series (de-
fined as studies with <10 participants) and articles
without original data.
Selection of studies
All titles and abstracts of the citations identified by our
literature search were independently screened by two in-
vestigators (AA-O and VFC-M). Relevant articles were
reviewed in their entirety. Each investigator made a rec-
ommendation for inclusion or exclusion of single articles
and if discordant, a third investigator solved the discrep-
ancy (CL). When 2 or more articles had overlap of their
populations and reported on the same outcomes, only
the most inclusive article was considered.
Data extraction, synthesis and analyses
Using a standardized form, we systematically collected
data on the outcomes of interest, the characteristics of
the populations studied, whether IE involved the right or
left heart valves, and several aspects of the study setting
and methodological design. For purposes of this review,
cure was defined as both microbiological and clinical
resolution of the infection. We used the McMaster Uni-
versity literature appraisal recommendations to evaluate
the quality of observational studies [7]; whereas for clin-
ical trials, we used the Consolidated Standards of
Reporting Trials (CONSORT) guidelines [8]. We made
every effort to calculate pooled incidence rates for the
outcomes of interest when feasible.
Results
Of a total of 709 titles retrieved by our search strategy,
25 articles were considered for review based on their
title and abstract. Hereafter, 14 more articles were ex-
cluded based on exclusion criteria (Additional file 2),
leaving 11 studies for the final analyses [9-19] (Figure 1).
Of these, 9 were observational [9-17] and 2 were ran-
domized controlled trials (RCTs) [18,19]. Tables 1 and 2
summarize the characteristics of the selected studies.
Observational studies
All observational studies involved patients that were
hospitalized at the moment of enrolment. Three (33%)
of these studies were of prospective design [10-12] and 6
(67%) were retrospective [9,13-17]. Two (22%) studies
focused on left- sided IE [9,12], one in right-sided IE
(11%) [10], and six (60%) did not specify this informa-
tion [11,13-17]. One study (11%) involved only intraven-
ous drug users (IVDUs) [10] and one (11%) involved
only paediatric cases [13] (Table 1).
Quality assessment
Only two studies (22%) established a uniform process
for patient enrolment [9,10]. One study (11%) relied on
modified Duke’s criteria for the diagnosis of IE [9]; two
studies (22%) used a combination of suggestive clinical
findings, echocardiographic findings and positive blood
cultures [10,11]; four studies (44%) made this diagnosis
based of the pre-existence of valvular disease and the
presence of suggestive clinical findings and/or positive
blood cultures [12,13,15,16]; and two studies (22%) did
not provide case definitions [14,17]. Only three studies
specified inclusion and exclusion criteria [9-11]. No
study provided comparative information for eligible pa-
tients that were not ultimately enrolled in the study or
did comparative analysis of outcomes relative to a con-
trol group. All studies gave information of outcomes for
all patients enrolled and provided enough information to
identify whether the institution in which the investiga-
tion was carried out was a referral center or not. The in-
dividual quality performance of each of these studies is
summarized in Table 3.
Therapy and outcomes
Four studies (44%) used oral antibiotic therapy for the en-
tire duration of treatment [11,14,16,17], two (22%) used
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oral therapy along with adjuvant parenteral streptomycin
for the first 2 weeks of treatment [12,15], and three (33%)
used oral therapy only after an initial short course (<2
weeks) of IV antibiotics [9,10,13]. Oral therapies included
beta-lactams (amoxicillin, penicillin V, ampicillin, cloxacillin
and dicloxacillin) - with or without probenecid - in five
(56%) studies [11-15]; fluoroquinolones (ciprofloxacin) in
combination with rifampin in one (16%) [10]; and sulfona-
mide, aureomycin and linezolid in one study each [9,16,17].
All studies described the microbiological aetiology of
their cases. Seven studies (78%) involved patients with
infections caused primarily by Streptococcus sp. [11-17],
while two (22%) included mainly cases of S. aureus dis-
ease [9,10]. All but one study [17] reported antibiotic
susceptibility of the etiologic bacteria.
The follow-up time widely varied among reports (4
weeks to 15 years). Seven studies (78%) reported cure
rates between 77-100% [9-15]. Two other studies, how-
ever, had failure rates of 90% [17] and 74% [16]. The
former of these involved cases of S. viridians IE treated
with oral sulfonamide [17]; whereas the latter used oral
aureomycin to treat S. viridans (55%), enterococcus
(18%), or culture negative (27%) IE [16] (Table 1).
Clinical trials
We identified 2 clinical trials. Heldman et al [18] focused
on right-sided IE caused by S. aureus in IVDUs whereas
Stamboulian et al [19] studied left-sided IE caused by
Streptococcus sp. (S. viridians 50% and S. bovis 50%)
(Table 2).
Quality assessment
Both studies used a combination of suggestive clinical
signs, positive blood cultures and echocardiographic find-
ings in their case definition of IE [18,19]. Both studies also
defined eligibility criteria, provided details of the setting
and location of the study, and gave a detailed description
of the intervention used. Only Heldman et al [18] detailed
the processes followed for ascertainment and measure-
ment of clinical outcomes, established adequate sequence
generation for randomization, analyzed data on the safety
of the intervention, described the participants’ flow in the
study, addressed concerns for incomplete outcome data
and risk of selective reporting, and provided information
on the accessibility to their study protocol, trial registra-
tion and the funding for their work. No study complied
with concealment or blinding of case allocation at the de-
livery of the study drug(s) or assessment of outcomes. The
individual quality performance of each of these studies is
summarized in Table 4.
Therapy used and outcomes
Heldman et al [18] compared 4-week courses of IV
vancomycin or oxacillin (with gentamicin for the first
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Figure 1 Flow diagram of the process for the selection of articles included in this review.
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Table 1 Observational studies of oral antibiotic therapy for infective endocarditis
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Table 1 Observational studies of oral antibiotic therapy for infective endocarditis (Continued)
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NVIE denotes cases of native valve infective endocarditis. PVIE denotes cases of prosthetic valve infective endocarditis. IV denotes intravenous. IVDUs denotes intravenous drug users. MSSA denotes methicillin-sensitive
S. aureus. MRSA denotes methicillin-resistant S. aureus. CoNS denotes coagulase-negative staphylococcus. GNB denotes gram-negative bacilli. Unless specified otherwise, all cohorts were primarily of adult patients. All





















five days) vs. oral ciprofloxacin plus rifampin. The cure
rates with oral and IV therapy were 89% and 90%, re-
spectively (P =0.9). However, drug toxicity was observed
in only 1 patient (2.8%) in the oral therapy arm versus
24 (61.5%) in the IV therapy arm (P <0.01). Adverse
events involved hepatotoxicity (1 patient in the oral ther-
apy arm and in 13 patients in the IV therapy arm), and
nephrotoxicity (10 patients in the IV therapy arm).
Stamboulian et al [19] compared a 4-week course of
IV ceftriaxone versus 2 weeks of IV ceftriaxone followed
by 2 weeks of oral amoxicillin (1 gm four times daily).
They reported 100% cure rate in both arms after a follow
up of six months (Table 2).
Discussion
The main findings of our review are: a) Reported cure
rates for IE caused by susceptible organisms and treated
with appropriate oral antibiotic regimens range between
77-100%; and b) Limited evidence from one small clin-
ical trial suggests that the combination of oral ciproflox-
acin and rifampin for the treatment of uncomplicated
right-sided IE caused by susceptible strains of S. aureus
in IVDUs could be as effective as, and produce less ad-
verse events than conventional IV antibiotic regimens.
Previous narrative reviews advocated a limited role for
oral antibiotics in the treatment of IE [4]. These opinions,
however, were largely based on theoretical considerations

































Colli et al [9] √ √ √ X X √ √
Dworkin et al [10] √ √ √ X X √ √
Chetty et al [11] X √ √ X X √ √
Pinchas et al [12] X √ X X X √ √
Phillips et al [13] X √ X X X √ √
Gray et al [14] X X X X X √ √
Campeau et al [15] X √ X X X √ √
Friedberg et al [16] X √ X X X √ √
Schein et al [17] X X X X X √ √
Table 2 Clinical trials of oral antibiotic therapy for infective endocarditis
Reference Cases Design Case definition Microbiology Therapy Results
Heldman et al,
USA [18]
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NVIE denotes cases of native valve infective endocarditis. IV denotes intravenous. IM denotes intramuscular. IVDUs denotes intravenous drug users. MSSA denotes
methicillin-sensitive S. aureus. MRSA denotes methicillin-resistant S. aureus. CoNS denotes coagulase-negative staphylococcus. All reports reported
follow-up ≥2 months.
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and anecdotal experience [4]. In contrast, this study is the
first systematic analysis of the existing published evidence
on this topic.
The success of antibiotics in controlling bacterial
growth and replication is dependent on: a) The suscepti-
bility of the pathogen to the anti-infective that is used;
b) The pharmacokinetics of this drug (i.e. whether its
bioavailability and distribution allow it to reach the site
of infection in sufficient concentration); and, c) Appro-
priate duration of therapy (especially when the 2 previ-
ous criteria are not fully met). Although the first
available formulations of antibiotics had unpredictable
absorption when given orally, more stable and absorb-
able compounds soon became available [4]. Oral beta-
lactams used in the studies of this review included,
among others, ampicillin, amoxicillin, phenithicillin and
penicillin V [11-15]. Although the pharmacokinetic pro-
file of oral ampicillin is known to be suboptimal [20],
the studies in which this antibiotic was used reported
high response rates [12-14]. This is likely explained by
the fact that the organisms causing IE in those series
were mainly streptococci (which remain highly sensitive
to beta-lactams to this date - penicillin MIC ≤0.12), and
that large doses of oral ampicillin were used, frequently
supplemented with probenecid [12,14]. Oral amoxicillin,
on the other hand, has excellent bioavailability (>90%)
and low binding to serum proteins (17%), which maxi-
mizes its tissue penetration [21]. Typical doses of oral
amoxicillin (1 g q8h) produce peak and 6-hour serum
concentrations of 16ug/ml and 1.1 ug/ml, respectively
[4,22,23]. Further, adding probenecid 1 g to each dose of
amoxicillin increases its peak and trough serum concen-
trations by 30% and 4-fold, respectively [22]. In our re-
view, we found only one observational study reporting
80% cure rate with oral amoxicillin in 15 cases of IE
caused mainly by susceptible streptococci, and one poor-
quality small clinical trial (n = 30) in which the use of
high-dose oral amoxicillin for 2 weeks after 2 initial
weeks of IV ceftriaxone resulted in the cure of all pa-
tients in the treatment arm [11,19]. Therefore, while
pharmacological considerations make oral amoxicillin a
plausible alternative for the treatment of IE caused by
susceptible bacteria, the clinical evidence supporting this
approach is still not robust. However, because strepto-
cocci continue to be a leading cause of IE (40% - 60% of
native valve endocarditis in the community setting) [1]
and oral amoxicillin is inexpensive and widely available,
this therapeutic approach should be further investigated
in adequately designed clinical trials. Beacause oral peni-
cillin V and phenithicillin also have favourable pharma-
cokinetic profiles, the same considerations apply to
these drugs [24-26].
S. aureus is the second most prominent cause of com-
munity acquired IE and the leading cause among those
who acquired the infection in healthcare settings and
among IVDUs [2]. Ciprofloxacin has bactericidal activity
against S. aureus and a favourable pharmacokinetic pro-
file when given orally (70% bioavailability and serum
protein binding rate of 30%), but the emergence of re-
sistance during treatment of S. aureus experimental dis-
ease is well described [27,28]. Similarly, rifampin is
bactericidal against S.aureus, has almost complete oral
bioavailability, and shows little binding to serum pro-
teins; however, it also has a low threshold for the devel-
opment of spontaneous resistance during therapy [29].
Although combining both agents has unpredictable ef-
fects in their anti-bacterial activity in vitro (i.e. synergis-
tic versus antagonistic), it consistently reduces the
development of resistance to either drug [30,31]. We
identified one prospective observational study [10] and
one randomized clinical trial [18] in which the combin-
ation of oral ciprofloxacin and rifampin proved not only
effective against uncomplicated S. aureus right-sided IE
in IVDUs but, in the latter case, it was better tolerated
than conventional IV therapy. However, the methodo-
logical limitations of these studies (Tables 3 and 4) war-
rant confirmatory investigations before this approach
could be widely adopted. In the meantime, this antibiotic
combination regimen should only be used in selected
cases for which currently favored IV regimens (including
beta-lactams or glycopeptides) are not suitable. Notably,
development of resistance to the combination of cipro-
floxacin and rifampin has been reported in at least one
human case of IE [32]. Newer fluoroquinolones such as
levofloxacin and moxifloxacin also have favourable
pharmacologic profile when given orally and are bacteri-
cidal against S. aureus, and in contrast to ciprofloxacin,
the development of in-vivo resistance appears rare
[27,33,34]. Both levofloxacin and moxifloxacin have also
proved effective in animal models of infective endocardi-
tis [35,36] and in anecdotal human cases [37,38]. There-
fore, it would also be reasonable to consider the oral
formulations of these drugs in future studies for the
treatment of this infection. We found that clinical ex-
perience with the use of oral anti-staphylococcal penicil-
lins such as cloxacillin and flucloxacillin (used in one
report of our review) [13] for the treatment of S. aureus
IE is very limited and therefore, this approach should
only be considered in controlled research settings.
Other oral antibiotics used in the reports identified by
our review include linezolid, aureomycin, sulphonamide,
and erythromycin [9,10,13,17]. Oral linezolid has excel-
lent pharmacologic profile (bioavailability >99% and
serum protein binding rate 30%) and there is a growing
body of evidence of its efficacy in serious infections
caused by Gram-positive cocci [39]. The promising re-
sults with the use of oral linezolid for the treatment IE
reported by Colli et al [9] warrant further confirmation
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in clinical trials. Aureomycin (chlortetracyclin) is an old
tetracycline derivative with almost complete GI absorp-
tion that is no longer available for clinical use [40]. Aur-
eomycin was only 36% effective in a small series of 11
patients with IE mainly due to E. faecalis and strepcocci
[16]. However, newer tetracyclines such as minocycline
and doxycycline (which also have excellent bioavailability
and are active against gram positive organisms) have
more recently been proposed as potential oral alterna-
tives for treatment of IE caused by common bacteria [4].
Doxycycline has long been used for treatment of Q fever
IE [41,42] but its unpredictable efficacy against S.aureus
would limit its use in other IE settings. Minocycline, on
the other hand, has consistent and reliable activity
against gram-positive organisms, including S. aureus,
and has been effective in animal models of IE caused by
this bacterium [43,44]. Anecdotal reports of clinical suc-
cess with the use oral minocyline in the treatment S.
aureus IE in humans further support its consideration in
future investigations [45,46]. The report by Schein et al
[17] describing single sulfa therapy (i.e. sulphonamide)
for IE has only historical relevance, as this therapy is no
longer available for oral use. Trimethroprim – sulfa-
methoxazole, however, a more contemporary sulfa-
containing drug with excellent oral bioavailability has
been shown to be inferior to vancomycin in treating un-
complicated right-side S. aureus IE in IVDU when given
intravenously [47]. Finally, experience with the use of
oral macrolides such as erythromycin in the treatment
of severe infections is very limited and the growing rates
of resistance to macrolides among streptococci and
staphylococci are a further concern [48-50].
Our review has limitations. It is possible that we
missed evidence beyond the boundaries of our search
strategies. As mentioned above, a majority of the studies
included in our analyses had poor methodological qual-
ity. The significant heterogeneity in their study popula-
tions and designs prevented us from calculating any
meaningful pooled estimates. Comprehensive analyses of
drug safety, side effects, and comparative costs were
largely lacking. We cannot rule out potential publication
bias against studies that found poor effectiveness of oral
antibiotic therapy in IE. Finally, since we limited our re-
view to studies in which no parenteral antibiotic was
used beyond the two weeks of treatment, the value of
oral regimens as step-down therapy for IE beyond this
time interval might have not been fully captured.
Conclusion
In conclusion, oral antibiotics with favourable pharma-
cokinetic profiles appear effective in treating selected
cases of IE caused by susceptible organisms. Because of
its favourable pharmacokinetic profile, high-dose oral
amoxicillin for the treatment of IE caused by susceptible
streptococci is particularly appealing but studies of bet-
ter quality are needed before further recommendations
can be made about this approach in clinical settings.
The same considerations apply to the use of oral linezo-
lid in cases of S. aureus IE. Oral combination therapy
with ciprofloxacin and rifampin appears to be an accept-
able alternative for the treatment of uncomplicated
right-side endocarditis caused by susceptible strains of S.
aureus in IVDUs but until adequate clinical trials are
available, this approach should be reserved for special
situations in which conventional IV antibiotic therapy is
not possible or it is undesirable. Ongoing and future in-
vestigations should help to better define the role of oral
antibiotics in the treatment of IE [51].
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